量研学術機関リポジトリ「QST-Repository」は、国立研究開発法人 量子科学技術研究開発機構に所属する職員等が生み出した学術成果（学会誌発表論文、学会発表、研究開発報告書、特許等）を集積しインターネット上で広く公開するサービスです。 Welcome to QST-Repository where we accumulates and discloses the academic research results(Journal Publications, Conference presentation, Research and Development Report, Patent, etc.) of the members of National Institutes for Quantum Science and Technology.
Thank you very much for using our website. On the 11th of March 2019, this site was moved from our own network server to the JAIRO Cloud network server. If you previously bookmarked this site, that bookmark will no longer work. We would be grateful if you could bookmark the website again. Thank you very much for your understanding and cooperation.
Purpose: Our previous research suggested FGF2 expression change would be an indicator for the efficacy of radiotherapy. Here, we validated this finding using newly enrolled patients and further investigated the mechanism of individual tumor radiosensitivity related with the FGF2 expression.
Experimental design: Sixty-nine patients were recruited as a validation set for immunohistichemical FGF2 expression in tumor cells (FGF2-T), using biopsy samples taken before or one week after initiation of radiotherapy. We also investigated the expression of FGF2 in tumor stroma (FGF2-S), VEGF and CD31 in 98 patients.
Results: FGF2-T significantly increased (P = 0.0037), and the ratio change of FGF2-T was significantly related with better prognosis (P = 0.028). Only tumors with positive FGF2-S in pretreatment samples increased VEGF expression (P = 0.035).
Conclusions: We confirmed our previous report for FGF2-T expression change. We also found the relationship between FGF2-S and VEGF during radiotherapy. These findings are indicative of the importance of combination timing and strict selection of patients in molecular target therapy after standard-of-care treatment.
子宮頸癌生検試料における放射線治療応答マーカーFGF２の発現
